

## RESEARCH

### BOB Economics Research | Weekly Wrap

Central Banks on hold, India expands fisc support

#### Ajanta Pharma | Target: Rs 1,900 | +18% | BUY

NDR takeaways – Earnings drivers tracking well

#### HCL Technologies | Target: Rs 920 | +15% | BUY

Acquisition spree on; DWS to expand footprint in Australia

## SUMMARY

### India Economics: Weekly Wrap

Major central banks kept the policy rates on hold with US Fed likely to keep ultra-low rates till 2023. On the other hand, BoE hinted at negative rates with downside risks to growth. Global yields and equities ended the week mixed. US\$ continued to depreciate. On the domestic front, Government sought Parliamentary approval for additional spending of Rs 1.69tn. Even so, India's 10Y yield fell by 3bps as RBI announced OMO purchase of Rs 100bn. Borrowing calendar will be published towards end of the month.

[Click here for the full report.](#)

### Ajanta Pharma

We hosted investor meetings with the management of Ajanta Pharma (AJP). AJP expects significant earnings acceleration over the next 3-4 years (>25% CAGR per our estimates). Key drivers include brand franchise recovery (India+EM), high-teens growth in the US, operating leverage from the new facility and capex tailwinds. We expect these factors to bolster operating margins to 30% by FY23 (27% in FY20), aiding a stock rerating. Raise FY21-FY23 EPS by 3-5% and Sep'21 TP to Rs 1,900 (vs. Rs 1,730). BUY.

[Click here for the full report.](#)

## TOP PICKS

### LARGE-CAP IDEAS

Company	Rating	Target
<a href="#">Bajaj Finance</a>	Buy	4,000
<a href="#">Cipla</a>	Buy	850
<a href="#">GAIL</a>	Buy	155
<a href="#">Petronet LNG</a>	Buy	310
<a href="#">Tech Mahindra</a>	Buy	910

### MID-CAP IDEAS

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	3,600
<a href="#">Chola Investment</a>	Buy	280
<a href="#">Laurus Labs</a>	Buy	1,200
<a href="#">Transport Corp</a>	Buy	270
<a href="#">Mahanagar Gas</a>	Sell	750

Source: BOBCAPS Research

### DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.69	1bps	3bps	(103bps)
India 10Y yield (%)	6.02	(2bps)	6bps	(77bps)
USD/INR	73.45	0.3	1.8	(3.5)
Brent Crude (US\$/bbl)	43.15	(0.3)	(5.1)	(32.9)
Dow	27,657	(0.9)	(0.4)	2.7
Shanghai	3,338	2.1	(3.3)	11.0
Sensex	38,846	(0.3)	0.8	2.2
India FII (US\$ mn)	17 Sep	MTD	CYTD	FYTD
FII-D	(36.3)	310.9	(14,779.1)	(5,019.6)
FII-E	(17.8)	563.0	5,370.4	11,973.3

Source: Bank of Baroda Economics Research

### BOBCAPS Research

research@bobcaps.in



## HCL Technologies

HCL Technologies (HCLT) acquired Australian IT firm DWS for US\$115.8mn. This acquisition serves the purpose of expanding HCLT's reach in Australia and New Zealand (ANZ) and brings in marquee ANZ clientele. DWS has domain expertise in BFSI and Govt. and defence verticals, together forming 72% of its revenues. These verticals are a safe bet during the ongoing pandemic. For the long term, this acquisition looks EPS accretive, though the gains will be negligible. Retain BUY.

[Click here](#) for the full report.

## WEEKLY WRAP

21 September 2020

## Central Banks on hold, India expands fisc support

Major central banks kept the policy rates on hold with US Fed likely to keep ultra-low rates till 2023. On the other hand, BoE hinted at negative rates with downside risks to growth. Global yields and equities ended the week mixed. US\$ continued to depreciate. On the domestic front, Government sought Parliamentary approval for additional spending of Rs 1.69tn. Even so, India's 10Y yield fell by 3bps as RBI announced OMO purchase of Rs 100bn. Borrowing calendar will be published towards end of the month.

Sameer Narang | Jahnavi

chief.economist@bankofbaroda.com

## Markets

- Bonds:** US 10Y yield rose by 3bps (0.69%) as Fed projected better growth outlook in CY20 (3.7% contraction against 6.5% contraction, estimated earlier). However, dot plot showed policy rate will be near zero till CY23. UK 10Y was flat (0.18%) as BoE hinted at negative rates. Oil prices rose by 8.3% (US\$ 43/bbl) due to supply disruption from Hurricane Sally. India's 10Y yield fell by 3bps (6.02%), supported by RBI's OMO purchase announcement of Rs 100bn. System liquidity surplus was at Rs 2.6tn as on 18 Sep 2020 compared with Rs 3.6tn in the previous week.
- Currency:** Except EUR other global currencies closed higher against the dollar. DXY fell by 0.4% this week as US macro data remained weaker than anticipated (industrial production, retail sales and housing starts). JPY rose by 1.5% to a 6-month high on safe haven demand. GBP also rose by 0.9% even as BoE hinted at negative rates. INR rose by 0.1% in the week supported by FII inflows of US\$ 527mn.
- Equity:** Global indices ended mixed as major central banks kept the policy rates on hold. Fed expects the rate to remain at current level till CY23. Shanghai Comp (2.4%) surged the most led by acceleration in industrial profits and retail sales. On other hand, Sensex ended flat with real estate gaining the most and banking stocks under-performing the most.
- Upcoming key events:** In the current week, markets will await flash PMI data of major economies, along with US housing and jobless claims data. On the domestic front, government's H2 borrowing calendar is awaited and markets will also look for further direction from RBI to control yield curve.



**BUY**

TP: Rs 1,900 | ▲ 18%

**AJANTA PHARMA**

Pharmaceuticals

21 September 2020

## NDR takeaways – Earnings drivers tracking well

We hosted investor meetings with the management of Ajanta Pharma (AJP). AJP expects significant earnings acceleration over the next 3-4 years (>25% CAGR per our estimates). Key drivers include brand franchise recovery (India+EM), high-teens growth in the US, operating leverage from the new facility and capex tailwinds. We expect these factors to bolster operating margins to 30% by FY23 (27% in FY20), aiding a stock rerating. Raise FY21-FY23 EPS by 3-5% and Sep'21 TP to Rs 1,900 (vs. Rs 1,730). BUY.

Vivek Kumar

research@bobcaps.in

**India business; FY21 decline but >10% growth from FY22:** Sales improved marginally in Q1FY21 led by gradual recovery in the acute portfolio (dermatology, ophthalmology). The chronic business is doing well, and MR activity has returned to normal. Trade generic share has picked up from 3% in Q1 to ~5% now and is likely to be capped at this level. In Jul/Aug'20, India sales grew 9.4%/8% vs. 0.2%/-2.2% for industry, per AIOCD. AJP expects a 5-6% decline in FY21 sales and >10% growth beyond.

Ticker/Price	AJP IN/Rs 1,613
Market cap	US\$ 1.9bn
Shares o/s	88mn
3M ADV	US\$ 4.4mn
52wk high/low	Rs 1,760/Rs 903
Promoter/FPI/DII	71%/9%/9%

Source: NSE

**US business- key 2H launches:** Some of the key H2 launches planned for the US are Tamiflu suspension and Divalproex DR (both 4-5-player markets). AJP pegs revenue potential for each at US\$ 5mn-6mn and expects >20% US growth in FY21. Strong pipeline visibility should drive high-teens growth in the next 3-4 years. Management expects US EBITDA margins of >25% by FY23.

## STOCK PERFORMANCE



Source: NSE

**EM – facing resistance:** Branded EM business (Asia, Africa) is slowing due to Covid restrictions; hence growth for the rest of Q2 could be moderate (Q1: >23% YoY). AJP expects EM growth of 7-8% in FY21. Tender business outlook in Africa markets is muted at least in next two years.

...(continued in next page)

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	20,553	25,878	27,199	31,046	35,317
EBITDA (Rs mn)	5,653	6,944	7,597	8,870	10,434
Adj. net profit (Rs mn)	3,869	4,082	4,888	6,147	7,599
Adj. EPS (Rs)	44.1	46.6	55.7	70.1	86.6
Adj. EPS growth (%)	(17.4)	5.5	19.7	25.7	23.6
Adj. ROAE (%)	17.8	16.6	17.1	18.7	19.8
Adj. P/E (x)	36.6	34.7	28.9	23.0	18.6
EV/EBITDA (x)	24.9	20.3	18.5	15.7	13.1

Source: Company, BOBCAPS Research



**BUY**

TP: Rs 920 | ▲ 15%

**HCL TECHNOLOGIES**

| IT Services

| 21 September 2020

## Acquisition spree on; DWS to expand footprint in Australia

**HCL Technologies (HCLT) acquired Australian IT firm DWS for US\$115.8mn. This acquisition serves the purpose of expanding HCLT's reach in Australia and New Zealand (ANZ) and brings in marquee ANZ clientele. DWS has domain expertise in BFSI and Govt. and defence verticals, together forming 72% of its revenues. These verticals are a safe bet during the ongoing pandemic. For the long term, this acquisition looks EPS accretive, though the gains will be negligible. Retain BUY.**

Ruchi Burde | Seema Nayak

research@bobcaps.in

**A tuck-in acquisition:** DWS has extensive capabilities in the BFSI and Govt./Federal verticals which form ~72% of its total revenues. These verticals have been more resilient vs. the rest during the pandemic. Its management expects the good growth to continue driven by assured federal projects and state govt. work. DWS' FY20 annual revenue stood at AU\$167.9mn, which is roughly 1%+ of HCLT's FY20 revenue. EBITDA margin excluding one off acquisition costs stands at 15-17%. Despite the pandemic, its revenue grew by 2.7% and underlying EBITDA margin by 80bps, YoY. Though its revenue growth has fluctuated over the years, its 5-year CAGR stood strong at 12% over FY15-20.


**Geographical diversification:** DWS' strong presence in Australia across Melbourne, Sydney, Canberra, Brisbane and Adelaide will help HCLT in geographic diversification. Out of its 150k employees, HCLT has only 1600 employees working in Australia. DWS will add its 700 employees to HCLT.

**EPS accretive:** Through small scale, this acquisition will be EPS accretive in our view. This acquisition will enhance HCLT's presence in Australia and New Zealand region especially in BFSI and Govt./defence segment creating potential for cross selling led synergies. Also, HCLT's robust track record with acquisitions is a plus.

Ticker/Price	HCLT IN/Rs 803
Market cap	US\$ 29.6bn
Shares o/s	2,713mn
3M ADV	US\$ 69.7mn
52wk high/low	Rs 850/Rs 375
Promoter/FPI/DII	60%/27%/13%

Source: NSE

## STOCK PERFORMANCE



Source: NSE

## KEY FINANCIALS

Y/E 31 Mar	FY19A	FY20A	FY21E	FY22E	FY23E
Total revenue (Rs mn)	6,04,280	7,06,780	7,52,867	8,42,502	9,21,977
EBITDA (Rs mn)	1,40,020	1,66,930	1,96,347	2,17,607	2,41,057
Adj. net profit (Rs mn)	99,757	1,10,940	1,24,938	1,35,450	1,53,388
Adj. EPS (Rs)	36.7	40.9	46.0	49.9	56.5
Adj. EPS growth (%)	16.3	11.5	12.6	8.4	13.2
Adj. ROAE (%)	25.2	23.5	22.5	21.8	22.0
Adj. P/E (x)	21.9	19.6	17.4	16.1	14.2
EV/EBITDA (x)	15.5	13.0	11.0	9.8	8.5

Source: Company, BOBCAPS Research



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 31 August 2020, out of 100 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 21 have ADD ratings, 11 are rated REDUCE and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.